PTC Therapeutics | PTCT - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xencor USD 81.86M 13.35M 2025-12